共 50 条
- [41] Bcl-xL and association with apoptosis following KRASG12C inhibition in KRASG12C mutant colorectal cancer.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Khawaja, HajrahBriggs, RebeccaLatimer, CherylRassel, Md A. M. B.Griffin, DarylHanson, LyndseyBardelli, AlbertoDi Nicolantonio, FedericaMcDade, SimonScott, ChristopherLambe, ShaunaMaurya, ManishaLindner, Andreas UlrichPrehn, Jochen H. M.Sousa, JoseWinnington, ChrisLaBonte, Melissa J.Ross, SarahVan Schaeybroeck, Sandra
- [42] Establishment and characterization of XPDX models with acquired or conditioned resistance to KRASG12C inhibitorsEUROPEAN JOURNAL OF CANCER, 2024, 211 : S145 - S146Moriarty, A.Flores, J.Johnson, S.Cesenes, P.Graciano, G.Lund, J.Banos, N.Papadopoulos, K.Patnaik, A.Rasco, D.Moreno, V.DeMiguel, M.Wick, M.
- [43] KRASG12C inhibition in colorectal cancer CommentLANCET ONCOLOGY, 2022, 23 (01): : 10 - 11Pfeiffer, PerQvortrup, Camilla
- [44] KRASG12C inhibition enhances immunogenicity in KRASG12C-mutant colorectal cancerCANCER RESEARCH, 2024, 84 (07)Patel, Parasvi S.Tian, Junde la Cruz, Ferran FeceCurtis, JacquelynPanda, ApekshyaOka, TomonoriDemehri, ShadmehrSade-Feldman, MosheKoptez, ScottCorcoran, Ryan B.
- [45] Sotorasib in KRASG12C mutated lung cancerLANCET, 2024, 403 (10422):Olivier, TimotheePrasad, Vinay
- [46] Cell Type-specific Adaptive Signaling Responses to KRASG12C InhibitionCLINICAL CANCER RESEARCH, 2021, 27 (09) : 2533 - 2548Solanki, Hitendra S.Welsh, Eric A.Fang, BinIzumi, VictoriaDarville, LanciaStone, BrandonFranzese, RyanChavan, SandipKinose, FumiImbody, DenisKoomen, John M.Rix, UweHaura, Eric B.
- [47] Acquired Resistance to KRASG12C Inhibition in CancerNEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (25): : 2382 - 2393Awad, M. M.Liu, S.Rybkin, I. I.Arbour, K. C.Dilly, J.Zhu, V. W.Johnson, M. L.Heist, R. S.Patil, T.Riely, G. J.Jacobson, J. O.Yang, X.Persky, N. S.Root, D. E.Lowder, K. E.Feng, H.Zhang, S. S.Haigis, K. M.Hung, Y. P.Sholl, L. M.Wolpin, B. M.Wiese, J.Christiansen, J.Lee, J.Schrock, A. B.Lim, L. P.Garg, K.Li, M.Engstrom, L. D.Waters, L.Lawson, J. D.Olson, P.Lito, P.Ou, S. -H. I.Christensen, J. G.Janne, P. A.Aguirre, A. J.
- [48] KRASG12C G12C Inhibitors in Non-Small Cell Lung Cancer: A ReviewONCOTARGETS AND THERAPY, 2024, 17 : 683 - 695Tang, MinWu, YijunBai, XiufengLu, You
- [49] Optimization of quinazolinone-based covalent inhibitors of KRASG12C in the discovery of AMG 510ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258Lopez, PatriciaAllen, JenniferAllen, JohnAmegadzie, AlbertAshton, KateBooker, ShonChen, JianChen, NingFrohn, MichaelGoodman, GuyKopecky, DavidLiu, LongbinLow, JonathanMa, VuNguyen, ThomasNishimura, NobukoPickrell, AlexanderReed, AnthonyShin, YoungsookSiegmund, AaronTamayo, NuriaTegley, ChristopherWalton, MaryWang, Hui-LingWurz, RyanXue, MayYang, KevinAchanta, PragathiBartberger, MichaelCanon, JudeMcCarter, JohnMohr, ChristopherRex, KarenSaiki, AnneSan Miguel, TishaVolak, LaurieWang, KevinWhittington, DouglasLipford, J. RussellCee, VictorLanman, Brian
- [50] Contribution of Noncovalent Recognition and Reactivity to the Optimization of Covalent Inhibitors: A Case Study on KRasG12CACS CHEMICAL BIOLOGY, 2024, 19 (08) : 1743 - 1756Peczka, NikolettRandelovic, IvanOrgovan, ZoltanCsorba, NoemiEgyed, AttilaPetri, LaszloAbranyi-Balogh, PeterGadanecz, MartonPerczel, AndrasTovari, JozsefSchlosser, GittaTakacs, TamasMihalovits, Levente M.Ferenczy, Gyorgy G.Buday, LaszloKeseru, Gyorgy M.